A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Julia Scarisbrick, Christiane Querfeld, Oleg Akilov, Martine Bagot, Raul Cordoba, Richard Cowan, Alejandro Martin Garcia-Sancho, Larisa Geskin, Auris Huen, Stephen Morris, Pablo Ortiz-Romero, Lauren Pinter-Brown, Ramon Pujol, Pietro Quaglino, Nakhle Saba, Lisa Shiue, Jatin Jadwani, Yi Liu, Payal Arora, Henry Zhao, Ragini Vuppugalla, Youn-H Kim
Institutions: City Of Hope National Medical Center, Beckman Research Institute, University of Pittsburgh, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, University of Manchester, The Christie NHS Foundation Trust, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Columbia University Irving Medical Center, Columbia University, The University of Texas MD Anderson Cancer Center, St Thomas' Hospital, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, University of California, Irvine, Hospital Del Mar, University of Turin, Louisiana State University Health Sciences Center New Orleans, Stanford University
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417018981